Abstract 672P
Background
Open sharing of synthetic trial data could facilitate secondary analyses and synthetic control arm development.
Methods
This study included 128 experimental vs. control treatments for solid tumors from 115 phase 3 randomized clinical trials (RCTs) published in 7 high-impact journals in 2023. Original individual patient data were reconstructed from the published Kaplan-Meier curves of overall survival (OS) in the intention-to-treat population. Either both arms (fully synthetic; retaining original sample size) or only the control arm (partially synthetic; retaining original control arm size) were synthesized using statistical models (Weibull and Synthpop) and a deep generative model (SurvivalGAN). Original and synthetic RCTs were compared through the probability overlap (0: none, 1: perfect) of the 95% confidence intervals (CIs) for the hazard ratio (HR), and the true (TPR) and false positive rate (FPR) with respect to the direction of the HR and its statistical significance on the 0.05 level.
Results
The median sample size was 571 (range 82-5637) and the median HR for OS was 0.80 (range 0.39-1.14) in the original (reconstructed) RCTs. Fifty-six (43.8%) were statistically significant, all of which showing superiority of the experimental treatment. The results presented in the table indicate that the use of synthetic arms may introduce bias due to generative model misspecification (in particular for fully synthetic RCTs created by Weibull) and additional variability inherent to the data generating process (more pronounced in fully vs. partially synthetic RCTs and in deep generative vs. statistical models), leading to insufficient CI overlap for the HR and thereby impacting statistical inference. TPR ranges from 2.6% to 80.4% and 90.9% to 98.2% in fully and partially synthetic RCTs, while FPR ranges from 25.0% to 46.4% and 27.8% to 44.4%, respectively. Table: 672P
Results of the synthetic RCTs
Approach | Model | Difference in log HR: mean (sd) | 95% CI overlap: mean (sd) | TPR: % | FPR: % |
Full | Weibull | 0.33 (0.43) | 0.43 (0.39) | 2.6 | 29.5 |
Full | Synthpop | 0.01 (0.20) | 0.84 (0.20) | 80.4 | 25.0 |
Full | SurvivalGAN | -0.01 (0.73) | 0.46 (0.35) | 66.0 | 46.4 |
Partial | Weibull | -0.11 (0.15) | 0.81 (0.23) | 90.9 | 32.4 |
Partial | Synthpop | -0.10 (0.25) | 0.85 (0.26) | 96.4 | 27.8 |
Partial | SurvivalGAN | -0.14 (0.23) | 0.71 (0.31) | 98.2 | 44.4 |
Conclusions
Naive inference from RCTs with synthetic arms may lead to overly optimistic or even wrong conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ghent University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Presenter: Hans Gelderblom
Session: Poster session 01
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01
639P - Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Presenter: Sophie Cousin
Session: Poster session 01